BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

543616

TLL

img img img img
No Data Available

Trident Lifeline Limited Share Price Update

As of the latest trading session, Trident Lifeline Limited share price is currently at ₹ 300, which is down by ₹ -5.00 from its previous closing. Today, the stock has fluctuated between ₹ 300.00 and ₹ 306.00. Over the past year, Trident Lifeline Limited has achieved a return of 8.28 %. In the last month alone, the return has been -0.89 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Trident Lifeline Limited fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    353.00

  • P/E Ratio (TTM)

    22.34

  • Beta

    0.13

  • Book Value / share

    72.09

  • Return on equity

    22.04%

  • EPS (TTM)

    13.57

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    4.94

info icon alternate text

Trident Lifeline Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 27.44
Operating Expense 22.07
Net Profit 4.94
Net Profit Margin (%) 18.00
Earnings Per Share (EPS) 4.26
EBITDA 7.49
Effective Tax Rate (%) 23.76
Particulars JUN 2025 (Values in Cr)
Revenue 18.82
Operating Expense 14.73
Net Profit 3.48
Net Profit Margin (%) 18.49
Earnings Per Share (EPS) 3.02
EBITDA 5.47
Effective Tax Rate (%) 24.83
Particulars MAR 2025 (Values in Cr)
Revenue 20.85
Operating Expense 16.45
Net Profit 4.35
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 3.79
EBITDA 7.18
Effective Tax Rate (%) 27.57
Particulars DEC 2024 (Values in Cr)
Revenue 16.51
Operating Expense 13.10
Net Profit 3.03
Net Profit Margin (%) 18.35
Earnings Per Share (EPS) 2.63
EBITDA 4.68
Effective Tax Rate (%) 23.29
Particulars SEP 2024 (Values in Cr)
Revenue 15.66
Operating Expense 11.67
Net Profit 3.39
Net Profit Margin (%) 21.64
Earnings Per Share (EPS) 2.95
EBITDA 4.94
Effective Tax Rate (%) 24.77
Particulars MAR 2025 (Values in Cr)
Revenue 67.80
Operating Expense 53.04
Net Profit 13.05
Net Profit Margin (%) 19.24
Earnings Per Share (EPS) 11.35
EBITDA 20.67
Effective Tax Rate (%) 27.07
Particulars MAR 2024 (Values in Cr)
Revenue 44.65
Operating Expense 37.05
Net Profit 7.04
Net Profit Margin (%) 15.76
Earnings Per Share (EPS) 6.22
EBITDA 11.03
Effective Tax Rate (%) 28.16
Particulars MAR 2023 (Values in Cr)
Revenue 31.69
Operating Expense 26.27
Net Profit 6.01
Net Profit Margin (%) 18.96
Earnings Per Share (EPS) 6.22
EBITDA 7.40
Effective Tax Rate (%) 8.52
Particulars MAR 2022 (Values in Cr)
Revenue 21.77
Operating Expense 19.39
Net Profit 3.95
Net Profit Margin (%) 18.14
Earnings Per Share (EPS) 4.93
EBITDA 3.31
Effective Tax Rate (%) -32.21
Particulars MAR 2021 (Values in Cr)
Revenue 9.62
Operating Expense 8.92
Net Profit 0.63
Net Profit Margin (%) 6.54
Earnings Per Share (EPS) 1.53
EBITDA 1.39
Effective Tax Rate (%) 25.88
Particulars MAR 2025 (Values in Cr)
Book Value / Share 56.05
ROE % 17.88
ROCE % 18.69
Total Debt to Total Equity 0.62
EBITDA Margin 26.74
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.14
ROE % 12.06
ROCE % 14.99
Total Debt to Total Equity 0.26
EBITDA Margin 23.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.69
ROE % 22.44
ROCE % 22.09
Total Debt to Total Equity 0.20
EBITDA Margin 23.45
Particulars MAR 2022 (Values in Cr)
Book Value / Share 5.97
ROE % 49.35
ROCE % 29.65
Total Debt to Total Equity 0.51
EBITDA Margin 15.25
Particulars MAR 2025 (Values in Cr)
Book Value / Share 57.16
ROE % 22.04
ROCE % 27.61
Total Debt to Total Equity 0.18
EBITDA Margin 30.69
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.81
ROE % 14.32
ROCE % 19.09
Total Debt to Total Equity 0.10
EBITDA Margin 24.82
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.68
ROE % 22.41
ROCE % 23.66
Total Debt to Total Equity 0.12
EBITDA Margin 23.41
Particulars MAR 2022 (Values in Cr)
Book Value / Share 5.97
ROE % 60.77
ROCE % 31.04
Total Debt to Total Equity 1.62
EBITDA Margin 15.25
Particulars MAR 2021 (Values in Cr)
Book Value / Share -0.94
ROE % 63.00
ROCE % 19.24
Total Debt to Total Equity 0.00
EBITDA Margin 14.66
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.46
Total Assets 156.00
Total Liabilities 156.00
Total Equity 69.64
Share Outstanding 11499200
Price to Book Ratio 4.50
Return on Assets (%) 7.53
Return on Capital (%) 9.5
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 6.65
Total Assets 87.07
Total Liabilities 87.07
Total Equity 53.95
Share Outstanding 11499200
Price to Book Ratio 3.58
Return on Assets (%) 7.28
Return on Capital (%) 8.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 13.77
Total Assets 62.57
Total Liabilities 62.57
Total Equity 47.10
Share Outstanding 11499200
Price to Book Ratio 4.01
Return on Assets (%) 9.61
Return on Capital (%) 10.98
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.15
Total Assets 13.83
Total Liabilities 13.83
Total Equity 4.77
Share Outstanding 8000000
Price to Book Ratio 0.00
Return on Assets (%) 28.53
Return on Capital (%) 54.61
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.11
Total Assets 97.79
Total Liabilities 97.79
Total Equity 65.72
Share Outstanding 11499200
Price to Book Ratio 4.50
Return on Assets (%) 13.34
Return on Capital (%) 16.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 6.00
Total Assets 73.23
Total Liabilities 73.23
Total Equity 52.67
Share Outstanding 11499200
Price to Book Ratio 3.58
Return on Assets (%) 9.61
Return on Capital (%) 11.96
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 13.76
Total Assets 56.49
Total Liabilities 56.49
Total Equity 45.63
Share Outstanding 11499200
Price to Book Ratio 4.01
Return on Assets (%) 10.64
Return on Capital (%) 12.27
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 13.82
Total Liabilities 13.82
Total Equity 4.77
Share Outstanding 8000000
Price to Book Ratio 0.00
Return on Assets (%) 28.55
Return on Capital (%) 54.61
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 11.44
Total Liabilities 11.44
Total Equity -0.47
Share Outstanding 5000000
Price to Book Ratio 0.00
Return on Assets (%) 5.52
Return on Capital (%) 15.59
Particulars MAR 2025 (Values in Cr)
Net Income 13.61
Cash from Operations -4.35
Cash from Investing -13.82
Cash from Financing 19.76
Net change in Cash -4.30
Free Cash Flow 6.74
Particulars MAR 2024 (Values in Cr)
Net Income 8.69
Cash from Operations 5.87
Cash from Investing -20.36
Cash from Financing 11.00
Net change in Cash -7.13
Free Cash Flow 23.76
Particulars MAR 2023 (Values in Cr)
Net Income 6.58
Cash from Operations -17.85
Cash from Investing -9.68
Cash from Financing 42.28
Net change in Cash 13.59
Free Cash Flow -10.93
Particulars MAR 2022 (Values in Cr)
Net Income 2.98
Cash from Operations -0.41
Cash from Investing -0.44
Cash from Financing 0.80
Net change in Cash 0.14
Free Cash Flow 0.04
Particulars MAR 2025 (Values in Cr)
Net Income 17.90
Cash from Operations 0.74
Cash from Investing -7.87
Cash from Financing 7.47
Net change in Cash -3.89
Free Cash Flow 5.96
Particulars MAR 2024 (Values in Cr)
Net Income 9.79
Cash from Operations 3.27
Cash from Investing -11.00
Cash from Financing 2.35
Net change in Cash -7.75
Free Cash Flow 12.35
Particulars MAR 2023 (Values in Cr)
Net Income 6.57
Cash from Operations -16.03
Cash from Investing -5.56
Cash from Financing 35.80
Net change in Cash 13.63
Free Cash Flow -13.76
Particulars MAR 2022 (Values in Cr)
Net Income 2.98
Cash from Operations -0.42
Cash from Investing -0.49
Cash from Financing 0.80
Net change in Cash 0.11
Free Cash Flow 0.03
Particulars MAR 2021 (Values in Cr)
Net Income 0.85
Cash from Operations 1.48
Cash from Investing -0.55
Cash from Financing -0.95
Net change in Cash -0.03
Free Cash Flow 2.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.75 13.60 1.44 212.66 27.02 / 68.00
BLISS GVS PHARMA LTD 171.05 16.49 1.59 1808.38 105.05 / 190.65
CIPLA LTD 1520.55 22.57 3.73 122825.65 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 269.00 7.07 2.02 791.69 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 27.75 22.56 3.86 212.66 27.02 / 68.00
AMRUTAJAN HEALTH LTD 655.35 33.42 5.53 1894.66 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9211.50 99.62 28.82 23028.75 6301.00 / 10653.05
BLISS GVS PHARMA LTD 171.05 23.08 1.63 1808.38 105.05 / 190.65

Trident Lifeline Limited shareholding pattern

Holding

28.77%
63.1%
7.7%
0.4%
3.43%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

Trident Lifeline Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
303.20 -0.59 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 306.90
  • 26 Days 306.30
  • 10 Days 307.70
  • 50 Days 301.80
  • 12 Days 307.70
  • 100 Days 294.30
  • 20 Days 307.20
  • 200 Days 283.50
303.45 PIVOT

First Support

301.60

First Resistance

306.85

Second Support

298.20

Second Resistance

308.70

Third Support

296.35

Third Resistance

312.10

RSI

48.35

ADX

14.12

MACD

1.42

Williams % R

-52.50

Commodity Channel Index (CCI)

-78.85

Date

2025-12-05

Week

11100.00

Same Day

6600.00

Month

9829.00

1 Year

0.14

3 Year

0.59

Over 1 Month

-0.89%

down

Over 1 Year

8.28%

down

Over 3 Months

10.37%

down

Over 3 Years

34.36%

down

Over 6 Months

11.79%

down

Over 5 Years

0.00%

down

Trident Lifeline Limited Corporate Actions

Trident Lifeline Limited Share Price

Trident Lifeline Limited was originally incorporated as Private Limited Company as 'Trident Lifeline Private Limited' on January 09, 2014. Subsequently, Company converted into a Public Limited and the name of Company was changed to 'Trident Lifeline Limited' on June 10, 2022. The Company is engaged in business of marketing ethical pharmaceutical products in domestic as well as international market. It is also engaged in distribution of pharmaceutical products through third party distribution network.

Apart from these, the Company offer wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan license. It operate in India as well as African, Latin American and East Indian Countries. Presently, it has presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venezuela.

Presently, Company operates with one contract manufacturer, who maintained relationship with the regular supplier, having FDA and WHO approved plant to supply pharma formulations. These units manufacture tablets, capsules, dry powder, syrup under their own brands. Pharma business operations are supported by various contract manufacturers having facilities which are approved by FDA/WHO and other relevant authorities. The Company typically work on contract manufacturing basis or at times purchase order basis, depending upon customer's requirement, with manufacturer of pharma products.

The Company deal in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. The product portfolio comprises of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflammatory drug (NSAIDS).

Company made an Initial Public Offering (IPO) of 34,99,200 Equity Shares of face value Rs 10/- each by raising funds from public aggregating to Rs 35.3 Crore in September, 2022.

The Company acquired 51% equity stake in TNS Pharma Private Limited, making it a subsidiary of the Company in 2023, TLL Herbal Limited became a subsidiary Company pursuant to acquisition of 51% equity shares w.e.f. August 10, 2023.

The Company incorporated TLL Elements Private Limited as wholly owned subsidiary of the Company on April 15, 2024. Further, on 2nd
December 2024, the Company acquired a 51% equity stake in TLL Parenterals Limited, which specializes in manufacturing a wide range of pharmaceutical products and medicinal products. Subsequently, on 4th February 2025, Company acquired a 51% equity stake in Trident Mediquip Limited, a company engaged in pharmaceuticals and medical devices.

Parent organization Indian Private
NSE symbol [-]
Founded 2014
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Trident Lifeline Ltd?

Answer Field

Trident Lifeline Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 303.20 as on Dec 05 2025 03:00 PM.

What is the Market Cap of Trident Lifeline Ltd Share?

Answer Field

The market cap of Trident Lifeline Ltd for NSE ₹ 0.00 & for BSE ₹ 353.00 as on Dec 05 2025 03:00 PM.

What is the 52 Week High and Low of Trident Lifeline Ltd?

Answer Field

The 52 Week High and Low of Trident Lifeline Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 324.95 and ₹ 222.00.

What is 1 year return for Trident Lifeline Ltd?

Answer Field

The 1 year returns on the stock has been 8.28%.

What is the P/E Ratio of Trident Lifeline Ltd Share?

Answer Field

As on Dec 05 2025 03:00 PM the price-to-earnings (PE) ratio for Trident Lifeline Ltd share is 22.34.

What is the PB ratio of Trident Lifeline Ltd Share?

Answer Field

As on Dec 05 2025 03:00 PM, the price-to-book (PB) ratio for Trident Lifeline Ltd share is 72.09.

How to Buy Trident Lifeline Ltd Share?

Answer Field

You can trade in Trident Lifeline Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Trident Lifeline Ltd Share on Bajaj Broking App?

Answer Field

To buy Trident Lifeline Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Trident Lifeline Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59